User profiles for Guilherme Pessoa-Amorim
 | Guilherme Pessoa-AmorimClinical Doctoral Fellow, University of Oxford Verified email at ndph.ox.ac.uk Cited by 18105 |
Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology
G Pessoa-Amorim, CF Camm… - … Journal-Quality of …, 2020 - academic.oup.com
Aims The COVID-19 pandemic required a significant redeployment of worldwide healthcare
resources. Fear of infection, national lockdowns and altered healthcare priorities have the …
resources. Fear of infection, national lockdowns and altered healthcare priorities have the …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6,
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, M Mafham, L Peto, M Campbell, G Pessoa-Amorim… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …
[HTML][HTML] Making trials part of good clinical care: lessons from the RECOVERY trial
G Pessoa-Amorim, M Campbell, L Fletcher… - Future Healthcare …, 2021 - ncbi.nlm.nih.gov
When COVID-19 hit the UK in early 2020, there were no known treatments for a condition
that results in the death of around one in four patients hospitalised with this disease. Around …
that results in the death of around one in four patients hospitalised with this disease. Around …
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic
properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
Impaired left atrial strain as a predictor of new-onset atrial fibrillation after aortic valve replacement independently of left atrial size
G Pessoa-Amorim, J Mancio, L Vouga, J Ribeiro… - Revista Española de …, 2018 - Elsevier
Introduction and objectives Left atrial dysfunction in aortic stenosis may precede atrial
enlargement and predict the occurrence of atrial fibrillation (AF). To test this hypothesis, we …
enlargement and predict the occurrence of atrial fibrillation (AF). To test this hypothesis, we …
[HTML][HTML] Left atrial 4D flow cardiovascular magnetic resonance: a reproducibility study in sinus rhythm and atrial fibrillation
M Spartera, G Pessoa-Amorim, A Stracquadanio… - Journal of …, 2021 - Elsevier
Background Four-dimensional (4D) flow cardiovascular magnetic resonance (CMR) allows
sophisticated quantification of left atrial (LA) blood flow, and could yield novel biomarkers of …
sophisticated quantification of left atrial (LA) blood flow, and could yield novel biomarkers of …
Epicardial adipose tissue volume and annexin A2/fetuin-A signalling are linked to coronary calcification in advanced coronary artery disease: Computed tomography …
Background & aims The role of epicardial adipose tissue (EAT) in the pathophysiology of
late stage-coronary artery disease (CAD) has not been investigated. We explored the …
late stage-coronary artery disease (CAD) has not been investigated. We explored the …
Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of
its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in …
its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in …
